Ampyra – improves walking speed for MS patients!

Ampyra has been covered in a couple of articles on the Medical News Today website this month. I first mentioned it in this blog in February 2009 (see: Ampyra). Here, I highlight the most important updated information.

Patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). The U.S. Food and Drug Administration approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with MS. This is the first drug approved for this use.

As of January 25th (only 2 days after the previous news was published) the statement goes:

The Food and Drug Administration has approved the drug fampridine-SR for the treatment of multiple sclerosis.

In addition, on the same date: Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA™ will be marketed in the U.S. by Acorda Therapeutics.

As of today (Jan. 26th.10) the firm has applied for a license to make the drug available in the UK.

Progressing quickly ; ) (one wishes they reacted as fast to the CCSVI news too hu? : p )

cheers!

Advertisements

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: